NASDAQ · SRZN
Surrozen, Inc.
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
Loading market information…
NASDAQ · SERA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sera Prognostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sera Prognostics, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sera Prognostics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -$0.20+16.67% vs estimate | $38.00K-24.0% vs estimate |
|---|
| Q4 2024 | Mar 19, 2025 | -$0.25-8.7% vs estimate | $24.00K+65.52% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.24-9.09% vs estimate | $29.00K-66.63% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $6.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
$2.06+$0.07 (+3.52%)
TuHURA Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.94% below the high.
$2.93-$0.02 (-0.68%)
SkyAI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.71% below the high.
$2.69+$0.08 (+3.07%)
Apyx Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 47.05% below the high.
$0.43+$0.02 (+5.03%)
Lucid Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.48% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
$0.43-$0.01 (-3.15%)
Oncolytics Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.1% below the high.
$0.79-$0.01 (-1.38%)
Rapid Micro Biosystems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.03% below the high.
